Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease Article Editorial Article uri icon

Overview

MeSH Major

  • Coronary Disease
  • Myocardial Infarction

abstract

  • The hypolipidemic action of fibrates has recently been shown to involve the activation of peroxisome proliferator activated receptors establishing a molecular mechanism for this class of drugs. Increasing clinical trial evidence supports the efficacy of fibrates in the treatment of dyslipoproteinemias, particularly in patients with hypertriglyceridemia and low high-density lipoproteins.

publication date

  • April 1998

Research

keywords

  • Editorial

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0002-9149(98)00010-1

PubMed ID

  • 9555782

Additional Document Info

start page

  • 912

end page

  • 7

volume

  • 81

number

  • 7